Диссертация (1140202), страница 18
Текст из файла (страница 18)
Р. 494-500.115123.Kamali S., Erer B., Artim-Esen A., Gul A., Ocal L., Konice M.,Aral O., and Inanc M. Predictors of Damage and Survival in Patients withWegener's Granulomatosis: Analysis of 50 Patients. J Rheumatol2010:37;374–8; doi:10.3899/jrheum.090387124.Greco A, RizzoMI, De Virgilio A, Gallo A, FusconiM, RuoppoloG, et al. Churg–Strauss syndrome.
Autoimmun Rev 2015;14:341–8.125.Dringenberg C, Apenberg S, Andrassy K. P-ANCA withmyeloperoxidase antibodies and c-ANCA with proteinase 3 antibodiesdefine a different vasculitis entity in patients with renal involvement. AdvExp Med Biol 1993;336:445–7.126.Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A,Guillevin L, et al. ANCA negative pauci-immune renal vasculitis:histology and outcome. Nephrol Dial Transplant 2005;20:1392–9.127.Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, KoldingsnesW,et al.
Development and validation of a consensus methodology for theclassification of the ANCAassociated vasculitides and polyarteritisnodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–7.128.Lionaki S, Blyth ER, Hogan SL et al.: Classification ofantineutrophil cytoplasmic autoantibody vasculitides: the role ofantineutrophil cytoplasmic autoantibody specificity for myeloperoxidaseor proteinase 3 in disease recognition and prognosis. Arthritis Rheum2012; 64: 3452-62.129.Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA.Value of ANCA measurements during remission to predict a relapse ofANCA -associated vasculitis--a meta-analysis. Rheumatology (Oxford)2012;51:100 -9130.al.Yamaguchi M, Ando M, Kato S, Katsuno T, Kato N, Kosugi T, etIncreaseofAntimyeloperoxidase116AntineutrophilCytoplasmicAntibody (ANCA) in Patients with Renal ANCA -associated Vasculitis:Association with Risk to Relapse.
J Rheumatol 2015;42:1853 -60.131.Correia P, Cameron JS, Ogg CS et al., End-stage renal failure insystemic lupus erythematosus with nephritis. Clin Nephrol 1984; 22: 293–302132.Weidanz F, Day CJ, Hewins P et al., Recurrences and infectionsduring continuous immunosuppressive therapy after beginning dialysis inANCA-associated vasculitis. Am J Kidney Dis 2007; 50: 36–46133.Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapyin antineutrophil cytoplasmic antibody-associated systemic vasculitis. JAm Soc Nephrol 1998; 9: 1258–1263134.KidneyDisease:ImprovingGlobalOutcomes(KDIGO)GlomerulonephritisWork Group.
KDIGO Clinical Practice Guideline forGlomerulonephritis. Kidney Int Suppl 2012; 2: 139–274135.Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration ofglucocorticoid therapy on relapse rate in antineutrophil cytoplasmicantibody-associated vasculitis: A meta-analysis. Arthritis Care Res2010;62:1166-73.136.Yamaguchi M, Ando M, Katsuno T, Tsuboi N, Maruyama S.Smoking Is a Risk Factor for Relapse of AntimyeloperoxidaseAntibodies-Associated Vasculitis. J Clin Rheumatol. 2018 Apr 5.
doi:10.1097/RHU.0000000000000737.137.Elefante E, Tripoli A, Ferro F, Baldini C: One year in review:systemic vasculitis. Clin Exp Rheumatol 2016; 34 (Suppl. 97): S1-6.138.Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemicvasculitis: clinical features and mortality. QJM 2005;98:97-111.139.A. J.
Mohammad, K. H. Mortensen, J. Babar, R. Smith, R. B. Jones,D. Nakagomi, P.Sivasothy and D. R.W. Jayne Pulmonary Involvement inAntineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis:117The Influence of ANCA Subtype. The Journal of Rheumatology.
2017.Doi: 10.3899/jrheum.16122/140.Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-ZubietaJA: Mortality in ANCA-associated vasculitis: a meta-analysis ofobservational studies. Ann Rheum Dis 2017; 76: 1566-74.141.Yamagata K, Usui J, Saito C et al.: ANCA- associated systemicvasculitis in Japan: clinical features and prognostic changes. Clin ExpNephrol 2012; 16: 580-8.142.Li ZY, Gou SJ, Chen M, Zhao MH: Predictors for outcomes inpatients with severe ANCA-associated glomerulonephritis who weredialysis-dependent at presentation: a study of 89 cases in a single Chinesecenter. Semin Arthritis Rheum 2013; 42: 515-21.143.Чучалин А.Г.
Первичные системные и легочные васкулиты.//Русский медицинский журнал. – 2001. - №21. – с. 912-918.144.Niles JL, Bottinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB,et al. The syndrome of lung hemorrhage and nephritis is usually anANCA-associated condition. Arch Intern Med 1996;156:440e5.145.Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTArecommendations for the management of ANCA-associated vasculitis.Ann Rheum Dis 2016 75(9):1583-94.146.Шилов Е.М., Смирнов А.В., Козловская Н.Л. Нефрология.Клинические рекомендации / под ред. Е.М. Шилова, А.В.
Смирнова,Н.Л. Козловской. – М.: ГЭОТАР-Медиа, 2016. – C. 569-574.147.Robson J, Doll H, Suppiah R et al. Damage in the ANCA-associated vasculitides: long-term data from the European VasculitisStudy group (EUVAS) therapeutic trials. Ann Rheum Dis 2015; 74: 177–184148.Mohammad AJ, Segelmark MA. Population-based study showingbetter renal prognosis for proteinase 3 antineutrophil cytoplasmic118antibody (ANCA)-associated nephritis versus myeloperoxidase ANCAassociated nephritis. J Rheumatol 2014; 41: 1366–1373149.Захарова Е.В. Прогнозирование исходов системной краснойволчанки и системных васкулитов с экстраренальными и почечнымипроявлениями: Дис.
... канд. мед. наук. – М., 2005. – 165 с.150.Lionaki S, Hogan SL, Jennette CE et al. The clinical course ofANCA smallvessel vasculitis on chronic dialysis. Kidney Int 2009; 76:644–651151.Charlier, C. et al. Risk factors for major infections in Wegenergranulomatosis: analysis of 113 patients. Ann. Rheum. Dis. 68, 658–663(2009).152.Reinhold-Keller, E.
et al. An interdisciplinary approach to the careof patients with Wegener’s granulomatosis—long-term outcome in 155patients. Arthritis Rheum. 43, 1021–1032 (2000).153.Little, M. A. et al. Early mortality in systemic vasculitis: relativecontribution of adverse events and active vasculitis. Ann. Rheum. Dis.69,1036–1043 (2010).154.Jones, R.
B., Walsh, M., Jayne, D. R. W. & European VasculitisStudy, G. Two-year follow-up results from a randomized trial of RTXversus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin.Exp. Immunol. 164, 57–58 (2011).155.Fauci A, Wolff S. Wegener's granulomatosis: studies in eighteenpatients and a review of the literature. Medicine 1973;52:53–61.156.Falagas, M.
E., Manta, K. G., Betsi, G. I. & Pappas, G. Infection-related morbidity and mortality in patients with connective tissuediseases: a systematic review. Clin. Rheumatol. 26, 663–670 (2007).157.Guillevin, L. et al. A prospective, multicenter, randomized trialcomparing steroids and pulse cyclophosphamide versus steroids and oral119cyclophosphamideinthetreatmentofgeneralizedWegener’sgranulomatosis. Arthritis Rheum. 40, 2187–2198 (1997).Hugle, B.
et al. Pneumocystis jiroveci pneumonia following158.rituximab treatment in Wegener’s granulomatosis. Arthritis Care Res. 62,1661–1664 (2010).Moosig, F., Holle, J. U. & Gross, W. L. Value of anti-infective159.chemoprophylaxis in primary systemic vasculitis: what is the evidence?Arthritis Res. Ther. 11, 1–11 (2009).Pyrpasopoulou, A. et al. Reactivation of chronic hepatitis B virus160.infection following rituximab administration for rheumatoid arthritis.Rheumatol. Int.
31, 403–404 (2011).Molloy, E. S. PML and rheumatology: the contribution of disease161.and drugs. Clev. Clin. J. Med. 78 (Suppl. 2), S28–S32 (2011).Suppiah, R. et al. A model to predict cardiovascular events in162.patientswithnewlydiagnosedWegener’sgranulomatosisandmicroscopic polyangiitis. Arthritis Care Res. 63, 588–596 (2011).Morgan, M. D. et al. Increased incidence of cardiovascular events163.inpatientswithantineutrophilcytoplasmicantibody-associatedvasculitides a matched-pair cohort study. Arthritis Rheum.
60, 3493–3500(2009).164.Н.А.П.И. Новиков, С.В. Моисеев, Е.И. Кузнецова, Е.Н. Семенкова,МухинИзменениеклиническоготеченияипрогнозагранулематоза с полиангиитом (Вегенера): результаты 40-летнегонаблюдения //Клиническая фармакология и терапия. – 2014. - Т.23,№1. – С. 32-37165.Houben E., Penne E.L., Voskuyl A.E., van der Heijden J.W., OttenR.H.J., Boers M., Hoekstra T. Cardiovascular events in anti-neutrophilcytoplasmicantibody-associated120vasculitis:ameta-analysisofobservational studies. Rheumatology (Oxford).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
